Article

CK induces morphological changes on histological study

Conductive keratoplasty (CK) produced collagen shrinkage changes in human corneas that were localized to 80% of the stromal depth compared with normal control corneas, according to Tatiana Naoumidi, MD.

Paris—Conductive keratoplasty (CK) produced collagen shrinkage changes in human corneas that were localized to 80% of the stromal depth compared with normal control corneas, according to Tatiana Naoumidi, MD.

Dr. Naoumidi and colleagues of the University of Crete Medical School, Greece, applied three CK spots to one cornea of 6 patients with peripheral keratoconus, all of whom had had penetrating keratoplasty (PK). The spots were applied in the periphery of the cornea; corneal buttons were assessed 1 and 3 days and 1, 3, and 6 month after the procedure.

Dr. Naoumidi reported at the annual meeting of the European Society of Cataract and Refractive Surgeons that on Days 1 and 3 after CK, there were small areas of detachment observed between the basal layer of the epithelial cells and Bowman's layer, which corresponded to the area that the top penetrated. On Day 7, the appearance of the epithelium was almost normal.

In all the corneal samples studied, the collagen layers had a crumpled appearance in up to 80% of the stromal depth and the affected area was cylindrical in shape with a diameter of 120 µm. Folds in Descemet's membrane between the CK spots were seen up to 6 months after the procedure.

"We found CK to be safe and efficient in that it caused changes in the corneal collagen that could be described as crumpled layers of collagen. The application reached the depth of 80% of the corneal thickness and the results were stable through the 6-month period of observation. The damage to the surrounding tissue was minimal," she concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.